Press Releases

Test Addition of New Press Release

Zalgen Relocates Headquarters to Life Sciences Epicenter in Frederick, Maryland

Leave a Comment / News, Press Releases / By

Frederick, MD, December 16, 2021 – One of the leading biotechnology and diagnostics companies in the field of neglected viral diseases with pandemic potential now calls a prime biotechnology and life sciences community its home, as Zalgen Labs LLC today announced its headquarters has relocated to Frederick, Maryland. Preparedness is Zalgen’s mantra. Founded on the concept of […]

Zalgen Relocates Headquarters to Life Sciences Epicenter in Frederick, Maryland Read More »

Zalgen Awarded CEPI Contract to Provide Test Kits for Largest Ever Lassa Fever Study in West Africa

Leave a Comment / Press Releases / By

Three-year contract leading to advance clinical trials for Lassa Fever vaccines reaffirms Zalgen’s focus on preparedness and its dedication to developing solutions for emerging viral threats Download the French Press Release Oslo, Norway & Germantown, Maryland, August 25, 2021 – Zalgen Labs LLC (Zalgen), a biotechnology and diagnostics company focused on preparedness for high impact, neglected

Zalgen Awarded CEPI Contract to Provide Test Kits for Largest Ever Lassa Fever Study in West Africa Read More »

Zalgen Licenses Lassa Virus Diagnostic Technology from The Scripps Research Institute

Press Releases / By

Scripps proprietary glycoprotein technology key to development of new diagnostic tests enabling the design of better, more effective vaccine programs for Lassa fever Zalgen Labs LLC (Zalgen), a biotechnology and diagnostics company focused on high-impact, neglected infectious diseases including Lassa Fever (LF), today announced that it has licensed proprietary technology developed by structural biologist Erica

Zalgen Licenses Lassa Virus Diagnostic Technology from The Scripps Research Institute Read More »

Zalgen Immunotherapeutic Demonstrates 100% Effectiveness Against Advanced Lassa Infections in Non-Human Primates

Press Releases / By

Article in Nature Medicine reports data from study at the University of Texas Medical Branch at Galveston (UTMB) showing protection against Lassa Fever, a major threat to global health Zalgen Labs LLC (Zalgen), a biotechnology and diagnostics company focused on high-impact, neglected infectious diseases including Lassa Fever (LF), today announced that Arevirumab-3, its lead immunotherapeutic

Zalgen Immunotherapeutic Demonstrates 100% Effectiveness Against Advanced Lassa Infections in Non-Human Primates Read More »

Zalgen Antibodies Used in Solving First Lassa Virus Glycoprotein Trimer Structure

Press Releases / By

Article in Science provides template for advanced vaccine and immunotherapeutic design against Lassa Fever, a major threat to global health Zalgen Labs LLC (Zalgen), a biotechnology and diagnostics company focused on high-impact, neglected infectious diseases including Lassa Fever (LF), today announced that its human monoclonal antibodies were used in an extensive research collaboration of the

Zalgen Antibodies Used in Solving First Lassa Virus Glycoprotein Trimer Structure Read More »

Zalgen and NOWDiagnostics Announce Strategic Collaboration to Advance Novel Rapid Diagnostic Tests for Tropical Diseases

Press Releases / By

Collaboration combines Zalgen’s leadership in hemorrhagic fevers and other tropical diseases with NOWDiagnostics’ unique ADEXUSDx® rapid test platform and GMP manufacturing capabilities Zalgen Labs LLC (Zalgen), a biotechnology and diagnostics company focused on high-impact, neglected infectious diseases, announced that it has entered into a series of agreements with NOWDiagnostics Inc. (NOWDx), an innovator in rapid

Zalgen and NOWDiagnostics Announce Strategic Collaboration to Advance Novel Rapid Diagnostic Tests for Tropical Diseases Read More »

Zalgen Labs Introduces Viral Diagnostics Business, Opens Advanced Product Development Center in Colorado

Press Releases / By

Zalgen Labs, a biotechnology and diagnostics company focused on high-impact, neglected infectious diseases, announced that it has received via transfer the viral hemorrhagic fever diagnostics business from Corgenix Medical Corporation and opened an advanced product development center in the Fitzsimons Bioscience Park Center on the University of Colorado Anschutz Medical Campus in Aurora, Colo. Zalgen

Zalgen Labs Introduces Viral Diagnostics Business, Opens Advanced Product Development Center in Colorado Read More »

Shopping Cart
Scroll to Top